[The uterine sarcoma, a new risk identified for tamoxifen].
Baron
M
M
Dessogne
P
P
d'Anjou
J
J
D000368:Aged; D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy; D002296:Carcinosarcoma / Q000139:chemically induced*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D020847:Estrogen Receptor Modulators / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008796:Metrorrhagia / Q000139:chemically induced; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D009570:Nitriles / Q000627:therapeutic use; D012306:Risk; D013629:Tamoxifen / Q000009:adverse effects*; D014230:Triazoles / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000139:chemically induced*
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D020847:Estrogen Receptor Modulators; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole